直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Withheld Prior Art and Inconsistent Arguments Used to Obtain FDA Approval Renders Patent Unenforceable

September 8, 2021

Authored and Edited by Kenneth S. Guerra; Elizabeth D. Ferrill; Caitlin E. Fowler

In Belcher Pharms., LLC v. Hospira, Inc., No. 2020-1799 (Fed. Cir. Sept. 1, 2021), the Federal Circuit affirmed the district court’s holding that U.S. Patent No. 9,283,197 is unenforceable due to inequitable conduct.

The asserted claims of the ’197 patent are generally directed to pharmaceutical epinephrine formulations having a pH between 2.8 and 3.3 and certain impurity levels.  The district court found that Belcher’s CSO, who was involved in the preparation of Belcher’s NDA and the prosecution of the ’197 patent, intentionally withheld a prior art reference and two prior art products that disclosed the claimed pH range and impurity levels.

The Federal Circuit affirmed, rejecting Belcher’s argument that its CSO genuinely believed the withheld prior art was immaterial.  Specifically, the Court noted that Belcher’s CSO drafted the NDA and cited withheld prior art to expedite approval of its NDA.  The Court further noted that during prosecution, the CSO argued that the claimed pH range was “critical” and yielded “unexpected results,” which contradicted Belcher’s arguments to the FDA.  Therefore, the Court found that there was no clear error in finding that the single most reasonable inference was that Belcher’s CSO possessed specific intent to deceive the PTO.

Read a full analysis of this case on Finnegan's IP FDA Blog. 

Tags

patentability, validity, defense, inequitable conduct, Food and Drug Administration (FDA), new drug application (NDA), United States Court of Appeals for the Federal Circuit (CAFC)

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Prosecution and Portfolio Management

Patent Drafting and Prosecution

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Washington, DC

Contacts

Kenneth S. Guerra
Associate
Washington, DC
+1 202 408 4124
Email
Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

2027 ABA-IPL Section Annual Meeting – IPLSPRING

April 14-15, 2027

Arlington

Conference

IAM Live: IPBC Europe 2027

March 15-17, 2026

Istanbul

Conference

Patent Litigation Europe 2027

January 18-20, 2027

Amsterdam

Seminar

Global Innovation Index: Perspectives on IP and Innovation Ecosystems

December 14, 2026

Washington, DC

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Osaka

December 10, 2026

Osaka

Webinar

Trade Secret Laws and Sausages: A Look at Efforts to Update the UTSA

December 10, 2026

Webinar

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Tokyo

December 8, 2026

Tokyo

Conference

Licensing Executives Society Chinese Taipei – Annual Conference 2026

December 4, 2026

Taipei

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP